Vor Biopharma (VOR) Stock Forecast & Price Target

Vor Biopharma is supported by telitacicept’s strong clinical validation, highlighted by the May 14, 2026 NEJM publication of the TELIGAN Phase 3 interim analysis showing a 55.0% placebo-adjusted reduction in 24-hour UPCR at week 39, preserved eGFR versus placebo, and fewer serious adverse events. Its outlook is further strengthened by repeated positive late-stage readouts across B-cell-mediated autoimmune diseases, existing approvals in China for SLE, RA, and gMG, and the potential to expand the U.S. addressable population from about 380K diagnosed patients to more than 1M with additional indications. Financially, the company’s exposure to telitacicept’s franchise value is reinforced by exclusive rights outside China and a reported $491.5M in net cash and cash equivalents, while global Phase 3 programs in gMG and SjD could broaden commercialization over time.

Vor Biopharma is exposed to significant fundamental risk because its outlook depends heavily on telitacicept succeeding in target indications, yet the company itself acknowledges that the program may fail clinically or regulatorily, or produce safety signals that could halt development. Even if development advances, the company faces the possibility of missing sales estimates and encountering strong commercial competition from current and future therapies, which would weaken the investment case. Manufacturing and shipment logistics add another layer of operational uncertainty, making the path from clinical promise to durable revenue unusually fragile.